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MEDAL REVIEW
Grafting mouse brains: from neurocarcinogenesis to
neurodegeneration
Adriano Aguzzi
Institute of Neuropathology, University Hospital of Zurich, Department
of Pathology, Schmelzbergstrasse 12, CH-8091 Zurich, Switzerland
Introduction
When I received a telephone call in early July 1998
breaking the news that I was to be awarded the EMBO
gold medal, I could not help but remember the awe with
which I had been looking upon my then-supervisor Erwin
Wagner a decade ago, when he was awarded the very
same prize. Since I was asked to write an autobiographical
review of my scientific activities, I dug out the medal
review by Erwin Wagner (1990) in an attempt to gather
some inspiration. The latter document is remarkable in its
scientific clarity, but also in its candor, typical of Erwin’s
personality. Along lines similar to those of Erwin Wagner’s
review article, I will try to trace my scientific motives
and achievements, and also describe the impact of the
scientists who taught me how to research the molecular
bases of diseases.
In 1979, the Italian undergraduate curriculum in the
medical sciences was utterly uninviting. Therefore,
although my home town of Pavia sports a distinguished
university, after no more than one semester I gave up my
enrollment at the medical faculty and decided to continue
my studies in Germany. Three years into medical school
in Freiburg im Breisgau, I felt the urge to learn the
methods of basic science. Thanks to the mediation of an
old friend, Gianpaolo Merlini (then a postdoc in New
York), I was given the opportunity to undertake an elective
in Soldano Ferrone’s laboratory at Columbia University,
where Patrizio Giacomini taught me how to make mono-
clonal antibodies, and introduced me to the then-
omnipresent methods of immunochemistry: sandwich
assays, radioimmunoprecipitation, immunofluorescence
and so on.
In 1983, as naı¨ve as this may seem with hindsight,
immunotherapy of cancer seemed to lie just around the
corner. A wealth of tumor antigens was being discovered,
and the booming technology of monoclonal antibodies
made it seem likely that one could soon use them as
magic bullets against cancer (Natali et al., 1983). Several
of the genes encoding interferons had been cloned (Nagata
et al., 1980; Gray et al., 1982), and since these substances
seemed to hold some promise in the therapy of malignant
melanoma, Patrizio and I deemed it reasonable to investi-
gate the effects of interferons on the expression of melan-
oma-associated tumor antigens (Giacomini et al., 1984,
1985b) and of histocompatibility antigens (Giacomini
et al., 1985a, 1986). At that time I would not have
imagined that, some 10 years later, I was to make the
acquaintance of some of the most prominent scientists in
the interferon field: Jean Lindenmann who discovered
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interferon (Isaacs and Lindenmann, 1957) and Charles
Weissmann who cloned the first interferon gene (Nagata
et al., 1980), and to initiate an extraordinarily fruitful
scientific collaboration with the latter, albeit in an area
which, to the best of our knowledge, is totally unrelated
to interferons.
As we all now know, tumor immunotherapy, with or
without interferons, in the years to come did not live up
to its early promise. While the last word may not yet have
been written on that subject, by the end of my medical
training I decided that I had had enough of tumor immuno-
logy and opted for moving upwards, i.e. into the central
nervous system. In July 1986 I took on a residency in
neuropathology with Paul Kleihues, then Director of the
Institute of Neuropathology at the University of Zurich.
Ever since the time of Alois Alzheimer, neuropathology
has been an exciting field, at the interface between clinical
medicine and basic science. When compared with our
colleagues in general histopathology, we neuropathologists
are a privileged lot: we do not need to spend much of our
time diagnosing warts and inflamed gall bladders under
the microscope. Also, since surgeons are in general more
inclined to remove gall bladders than brains, the total
diagnostic workload of neuropathologists is often less than
that of general pathologists. Such privileges, however,
also bear duties, and therefore one should insist that
respectable neuropathologists in academic institutions be
engaged in scientific activities, and whose excellence
should be measured by the same standards as our col-
leagues in the natural sciences.
Zurich, part I: brains of humans and mice
The bread-and-butter of neuropathology is the diagnosis
of neuroectodermal tumors resected by neurosurgeons and
neurodegenerative diseases, the latter being, for obvious
reasons, mainly a post mortem exercise. I found both of
these fields exciting enough to dedicate the next 12 years
of my scientific career to them. Besides being an eminent
morphologist, and the driving force behind the current
World Health Organization classification of brain tumors,
Paul Kleihues was obsessed with the problem of carcino-
genesis in the nervous system, and by the events driving
progression of benign gliomas to states of higher malig-
nancy. I was assigned the project of investigating whether
expression of tyrosine kinase oncogenes of the src family
might initiate glioma tumorigenesis in mice.
Since the activity of c-src is tightly regulated by tyrosine
phosphorylation of the SRC protein (Cooper et al., 1986;
Thomas et al., 1991), I feared that overexpression of c-src
in transgenic mice might not be helpful in reaching
the above goal, and thought it more promising to use
constitutively active SRC variants. Unavoidably, I came
across the work of Erwin Wagner who had pioneered the
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Fig. 1. (A) Endothelial hemangiomas induced in neural grafts by mT
antigen. Frontal hemispheric section through the brain showing a large
multichambered hemangioma and multiple hemorrhages in the graft.
The vessels have been visualized by perfusion with indian ink–gelatin.
(B) A large glioblastoma-like brain tumor, originating from a v-src
expressing graft and destroying the surrounding brain tissue. High
levels of v-src mRNA are detected by radioactive in situ hybridization:
dark areas correspond to high density of silver grains. While viable
tumor cells uniformly express high levels of v-src, unlabeled areas
within the tumor represent necrotic tissue.
field of in vivo analysis of oncogenes with transgenic
mice. A few days later I drove to Heidelberg (with Otmar
Wiestler and Roy Weller, a British neuropathologist on
sabbatical in Zurich) to meet Erwin at EMBL and to
discuss a possible collaboration. I thought it might be
interesting to express the viral v-src oncogene or the
middle-T antigen of polyoma virus, which binds and
activates SRC along with several other enzymes
(Courtneidge and Smith, 1983), in astrocytes of mice.
However, I soon learnt from Lindsay Williams and
Catherine Boulter that constitutive expression of either
gene would kill mice during embryogenesis (Williams
et al., 1989; Boulter et al., 1991). Consequently, generation
of transgenic or chimeric mice with any of the systems
available at that time might not prove useful in investigat-
ing whether these proteins were tumorigenic for neural
tissue, and which kind of tumors they would induce. We
therefore transduced primary embryonic neuroectodermal
cells of rats with v-src, middle T and c-src527Tyr→Phe using
replication-defective retroviral vectors, and resorted to
neural transplantation into wild-type hosts to analyze
the consequences. While middle T induced cavernous
hemangiomas in the brains of recipient animals, v-src led
to the development of astrocytomas (Aguzzi et al., 1991)
(Figure 1), yet when middle T was introduced into
the germ line of mice using a very similar construct,
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neuroblastomas developed (Aguzzi et al., 1990). Several
years later, I (with the help of my co-workers Gerhard
Malin, Jakob Weissenberger and Joachim Steinbach) ended
up hooking v-src to the glial fibrillary acidic protein
(GFAP) promoter, and producing what still seems to
be the only available transgenic model for astrocytoma
development (Weissenberger et al., 1997). Only few
GFAP–v-src transgenic mice develop full-blown astro-
cytomas, but all display preneoplastic lesions: this renders
them potentially useful in identifying the genetic lesions
responsible for progression of gliomas to malignancy.
We are currently pursuing the latter idea using proviral
tagging and grafting of GFAP–v-src neuroectodermal
tissue (T.Afanasieva, T.Voigtla¨nder, M.G.D’Angelo and
A.Aguzzi, unpublished material), an approach similar
to the classic studies of Anton Berns on lymphoma
development in mice infected with Moloney murine leuke-
mia virus (Jonkers and Berns, 1996).
The Vienna experience
The application of in vivo gene transfer methodologies to
neuropathological questions fascinated me. Therefore it
seemed logical to join Erwin Wagner, who had just been
appointed to the Institute of Molecular Pathology in
Vienna. With Erwin’s and Max Birnstiel’s generous sup-
port, I had the opportunity to set up a tiny unit of
‘molecular morphology’ (dealing with techniques such as
in situ hybridizations) and to analyze genotype–phenotype
correlations in a variety of transgenic models of disease
(Wagner and Aguzzi, 1992; Hilberg et al., 1993; Thomas
et al., 1993; Kiefer et al., 1994; Magyar et al., 1994). It
was Ivan Horak and my former brother-in-study Axel
Rethwilm who sparked my interest in transgenic models
of neurodegenerative diseases, and together with them I
spent the next several years attempting to understand the
neural damage occurring in transgenic mice expressing
genes of the human foamy virus (HFV), a relatively
obscure retrovirus which had been claimed to be prevalent
in certain regions of Africa. The detailed analysis of HFV
transgenic mice led to the identification of viral genes
responsible for the various aspects of their complex
neurodegenerative phenotype (Bothe et al., 1991; Aguzzi
et al., 1992a,b, 1993; Aguzzi, 1993; Netzer et al., 1993;
Marino et al., 1995; Tschopp et al., 1996; Lampe et al.,
1998). Even now, the system has not lost any of its
fascination; since HFV is extremely promiscuous in its
choice of host cells, there is some hope that the elimination
of the determinants of neurotoxicity may lead to its
exploitation as a versatile vector for gene therapy (Bieniasz
et al., 1997; Schmidt et al., 1997).
After three years of intimacy with transgenic mice, I
desperately wanted to move back into clinical neuropatho-
logy. I therefore returned to Zurich, and took up a position
as registrar in neuropathology in July 1992. A few months
before my departure from Vienna, Erwin had taken me
along to a meeting of the Schering Foundation in Berlin
on ‘transgenic models of disease’, and it was there that I
had the occasion to spend a memorable evening with
Charles Weissmann. By then, Weissmann had been
working on prion diseases for almost a decade, and his
achievements in this field were instrumental in shifting
prion research from rather esoteric grounds to the domain
Medal review
Table I. Definitions of prion-related terms
Term Definition
Prion Agent of transmissible spongiform encephalopathy (TSE), with unconventional properties. The term does not have
structural implications other than that a protein is an essential component.
‘Protein-only’ hypothesis Maintains that the prion is devoid of informational nucleic acid and consists of protein (or glycoprotein) as its
essential pathogenic component. Genetic evidence strongly suggests that the protein is an abnormal form of PrP.
The association with other ‘non-informational’ molecules (e.g. lipids or glycosamino glycans) is not excluded.
PrPC or PrP-sen The naturally occurring form of the mature Prnp gene product. It is glycosylated, anchored to the plasma membrane
by a GPI residue and poor in β-sheet structure. Its presence in a given cell type is necessary but not sufficient for
the replication of the prion.
PrPSc or PrP-res An ‘abnormal’ form of the mature Prnp gene product found in tissue of TSE sufferers, operationally defined as
being partly resistant to proteinase K digestion under defined reaction conditions. It is believed to differ from PrPC
only (or mainly) conformationally and is rich in β-sheet structure. Within the framework of the ‘protein-only’
hypothesis it is often considered to be the transmissible agent or prion.
Prnp The cellular gene encoding the PrPC protein. In addition to Prnpo/o mice, the most relevant transgenic mice used in
the studies described here include tga20 mice which express a ‘half-genomic’ Prnp transgene and are hypersensitive
to scrapie (Fischer et al., 1996), and tg33 mice which express PrP under control of the T lymphocyte-specific lck
promoter (A.J.Raeber, A.Sailer, T.Ru¨licke, S.Brandner, M.Klein, M.Fischer, A.Aguzzi and C.Weissmann,
unpublished data).
These definitions describe the terminology used in Zurich, which is not agreed on by convention and is therefore not necessarily used by others.
of solid molecular biology. Amongst other things, Charles
had isolated Prnp (Table I), the gene which encodes the
normal prion protein PrPC, thereby providing crucial
evidence in favor of Stan Prusiner’s ‘protein-only’ hypo-
thesis of prion replication, and suggesting the possibility
that infectious prions might replicate by recruitment and
conversion of normal prion protein (Oesch et al., 1985,
1988; Basler et al., 1986). He had also produced a
remarkable amount of theoretical work on the protein-only
theory (Weissmann, 1989, 1991a,b). With his colleagues
Michel Aguet and Hansru¨edi Bu¨eler, Charles had gone on
to create Prnp knockout mice (Bu¨eler et al., 1992).
Zurich, part II: tracking prions
Charles Weissmann was not entirely happy with the
histopathological analysis of these mice, and when he
learnt that I intended to move to Zurich he immediately
proposed that we collaborate on the attempt of infecting
Prnpo/o mice with a mouse-adapted strain of the sheep
scrapie agent. Sure enough, knockout mice stayed healthy
and displayed no neuropathological changes in their brains
(Bu¨eler et al., 1993); moreover, they did not support
replication of the infectious agent (Sailer et al., 1994). My
involvement in these now-famous studies was essentially
restricted to histopathological analyses: it is typical of
Charles Weissmann’s generosity that he let me participate
in this project, and also in fact in all other prion-related
experiments in his laboratory. Ever since, Weissmann
unconditionally and enthusiastically supported my wish
to establish my own prion research program.
My initial desire was to elucidate the pathogenetic
events which are initiated by the introduction of prions into
the brain, and which eventually result in the tremendous
cerebral damage typical of patients who develop Creutz-
feldt–Jakob disease. Almost nothing was known about the
molecular basis of this process. In theory, CNS damage
could occur because of PrPSc toxicity, or because the
conversion of PrPC into PrPSc may abruptly reduce its
availability to cellular processes for which it may be
6109
needed. The fact that Prnp knockout mice do not suffer
from spontaneous scrapie does not necessarily rule out
the second hypothesis, since absence of PrPC from early
development may arguably be compensated for more
easily than withdrawal during adult life.
By then, we had learnt much about the biology of
neural grafts (Isenmann et al., 1995, 1996a,b), and I had
convinced myself that the neurografting technology could
be useful for addressing a variety of questions, not
necessarily related to carcinogenesis. Therefore, it was
only logical to try to figure out whether neurografting
could represent a possible approach to the question of
prion neurotoxicity. My original idea was that a piece of
brain highly overexpressing PrPC grafted in the middle of
a Prnpo/o brain might, once infected, serve as a continuous
source of PrPSc. At this point I had some luck: Sebastian
Brandner had started as an intern in neuropathology and
did not feel sufficiently challenged with the clinical tasks
Paul Kleihues had assigned to him. Sebastian volunteered
to devote his spare time to the grafting experiment detailed
above, and this was the beginning of a collaboration which
has evolved over the last six years. Predictably, prion-
infected neurografts derived from PrP-overexpressing
transgenic donors, designated tga20 (Fischer et al., 1996),
and infected with prions underwent severe degeneration
(Figure 2), yet PrP-deficient host mice did not develop
clinical symptoms of disease, and brain tissue surrounding
the grafts was histologically unaffected despite significant
leaks of PrPSc from the graft (Aguzzi et al., 1996; Brandner
et al., 1996a). Therefore, expression of PrPC is important
not only for replication of the pathological agent, but also
for initiation of pathogenesis: PrPC-deficient neurons failed
to succumb to scrapie despite chronic exposure to the
agent and to PrPSc. These two terms, given the current
state of knowledge, do not necessarily indicate the same
physical entity (Aguzzi and Weissmann, 1997). The appar-
ent lack of clinical symptoms in mice harboring a scrapie-
sick graft allowed us to determine what would happen if
the disease was allowed to progress for a longer period
than the usual life span of mice. Under such circumstances,
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Fig. 2. Histopathology characteristic of scrapie in grafts infected with RML prions. Two hundred and sixty days after inoculation, the graft, which is
expressing high levels of PrPC, has undergone spongiform degeneration. While there is some mild gliosis in the Prnp–/– tissue surrounding the graft
(most likely due to the mass-shifting effect of the graft, and often seen also in mock-inoculated animals), note that degeneration is strictly confined
to the PrPC-expressing tissue. Left, Luxol (white matter stain); right, immunostain for GFAP (a marker of activated astrocytes).
we found neurons to be virtually wiped out while other
cell types turned out to be essentially resistant to the
disease (Brandner et al., 1998).
In March 1996, the Edinburgh neurology group of
Robert Will described the occurrence of a new variant
of Creutzfeldt–Jakob disease (nvCJD) which occurred
exclusively in very young individuals (Will et al., 1996),
and which much circumstantial evidence is incriminating
as being caused by the infection of humans with the agent
of bovine spongiform encephalopathy (BSE) (Aguzzi,
1996; Aguzzi and Weissmann, 1996; Weissmann and
Aguzzi, 1997). The impact of the BSE crisis on the prion
research community was already becoming enormous, and
was precipitated by this dramatic announcement. From its
status of a ‘non-existent’ disease (as one neurologist in
Zurich recently described it), Creutzfeldt–Jakob disease
had become a household word literally overnight. It
became compelling to wonder whether the research we
were doing might bear any practical relevance to the
question of whether and how the BSE agent can get into
the brain of humans. After all, intracerebral inoculation
with prions, though convenient for eliciting spongiform
encephalopathy in experimental animals with high effici-
ency and with minimal latency, is not really the most
common method of infection in real life. How do prions,
when entering the body through extracerebral sites, manage
to reach the central nervous system, which is the only
place in the body where they are capable of wreaking
havoc? Within the framework of the protein-only hypo-
thesis, at least in its most simplified incarnation, it might
be appealing to speculate that single molecules of the
scrapie agent might just randomly diffuse through the
body, and with some bad luck (from the viewpoint of the
patient) hit a nerve cell and start the chain reaction which
ultimately leads to spongiform encephalopathy.
One argument, however, deposes strongly against this
hypothesis: the latency period from inoculation into the
peritoneal cavity to onset of clinical symptoms and to
death of experimental animals, is extremely precise.
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Although such latency typically extends for 200–250 days,
depending on the prion and mouse strains used, its standard
deviation when inoculating a defined number of infectious
units of scrapie infectivity into the peritoneum of mice is
typically in the range of a few percent. Such a precise
process bears resemblance to the functioning of Swiss
clockwork, and one is reluctant to believe that it is due
to a random diffusion event. Besides which, a neuro-
pathologist’s clinical experience teaches that most neuro-
tropic viruses have evolved extremely sophisticated
mechanisms of invading the brain once inoculated into
distant sites. Think of herpes viruses or of rabies virus,
both of which exploit retrograde axonal transport and have
been conveniently used as tracers to identify networks of
neuronal connectivity.
In the case of scrapie prions, a considerable body of
older evidence indicated that the peripheral nervous system
plays an important role in prion neuroinvasion. In the
1970s, the scientists at the Neuropathogenesis Unit of
Edinburgh demonstrated that neural projections, both in
the central and in the peripheral nervous system, were
pivotal to prion spread; when injected into the footpad or
the peritoneal cavity, prions were shown to replicate
first in those segments of the spinal cord where the
corresponding spinal nerves projected. Intraocular injec-
tion led to targeting of the contralateral colliculus superior
as expected by the neuroanatomy of the retinotectal
projection pathway (Fraser, 1982). The other relevant
player in neuroinvasion, which had been identified already
when we started our work, was the immune system.
Elegant studies by Tetsuyuki Kitamoto (Kitamoto et al.,
1991) and others (O’Rourke et al., 1994; Lasmezas et al.,
1996) had shown that the lack of an intact immune system
would prevent neuroinvasion of prions administered to
the peritoneal cavity of mice.
If prions utilize these organ systems to spread throughout
the body, which molecules are necessary for this process?
Once identified, such molecules could be used to interfere
with the spread of prions. A straightforward assumption
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was that PrPC itself might represent a crucial element. PrP
is not only expressed in the central nervous system but in
many other cells of the body, most notably lymphocytes.
But how to detect spread of infectivity to the nervous
system if one uses PrP-deficient mice? Such mice are, as
repeatedly shown by several groups (Bu¨eler et al., 1993;
Manson et al., 1994; Sakaguchi et al., 1995), totally
resistant to scrapie and cannot replicate the agent. We
resorted to introducing a neural graft, which in this case
would act as an indicator of neuroinvasion. If the graft
developed histopathologically recognizable disease, and
accumulated PrPSc and infectivity, this would indicate that
neuroinvasion had taken place. It turned out that peripheral
inoculation at all the sites we tried never sufficed to
achieve neuroinvasion in this system. This was true for
the eye, the peritoneal cavity and the footpad.
At first blush, these results would seem to indicate that
the absence of normal prion protein totally prevents
neuroinvasion in addition to preventing replication of the
agent and neurotoxicity. However, the initial enthusiasm
we had developed for this theory became somewhat
dampened when Charles Weissmann critically reviewed
the data and suggested that Prnp knockout mice, which
have never seen normal prion protein before in their life,
might develop a humoral immune response against PrP
when grafted with neuroectodermal tissue heavily over-
expressing this protein. Upon his suggestion we looked
for evidence of such an immune response, and to our
consternation we promptly found it: Western blots of
recombinant and mammalian PrP probed with serum of
grafted PrP-deficient mice indicated high titers of anti-
PrP antibodies (Brandner et al., 1996b).
Therefore, it was not clear whether the spread of prion
infectivity was prevented by the presence of antibodies or
by the absence of PrP. Thanks to the helpfulness of
Andreas Sailer, Alex Raeber and Charles Weissmann, we
could use a line of mice called tg33, which they had
developed for other purposes and which expresses high
levels of PrP in T-lymphocytes. Presumably due to clonal
deletion during thymic development, these mice are incap-
able of mounting an anti-PrP immune response. When we
repeated the experiment with tg33 mice, we found that
intraocular (but not intraperitoneal) inoculation still failed
to produce disease in the graft. Therefore, at least for the
intraocular route, we concluded that absence of PrP
effectively prevents the spread of prions (Brandner et al.,
1996b). This does not necessarily mean, however, that
anti-PrP antibodies will not prevent prion spread, and
Christine Musahl and Ivan Hegyi are pursuing this question
using transgenic and immunological techniques.
Given the large amount of literature supporting an
important role of the immune system in prion spread, we
embarked on a bone marrow grafting enterprise using
PrP-expressing mice (wild-type or tga20 transgenic) as
donors, and Prnp knockout mice with a PrP-expressing
graft in their brain as recipients. Thomas Bla¨ttler, a student
in my laboratory who in the meantime has gone on to
become a neurologist, has been performing these studies
with significant help from the crew of Rolf Zinkernagel.
Thomas found that this manipulation sufficed to restore
accumulation of prions in spleen, and we were certainly
predicting that it would suffice to restore neuroinvasion.
Instead, we were almost shocked to learn that the contrary
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was in fact the case (Figure 3). We detected scrapie
histopathology in only one of 28 grafts of bone marrow-
reconstituted mice. This led us to propose a model in
which the immune system is important for moving prions
from the site of injection to lymphatic organs; however,
PrP expression in peripheral nerves might be crucial for
actual neuroinvasion (Bla¨ttler et al., 1997).
Unfortunately, the latter hypothesis was to prove rather
resilient to all attempts at positive experimental verifica-
tion. Ideally, one would wish to reconstitute expression
of PrPC on peripheral nerves selectively and show this
manipulation to be sufficient for restoration of neuroinva-
sion. We are attempting to achieve this with the help of
PrP-transducing adenoviral vectors which were generated
by Eckhard Flechsig and Charles Weissmann. Conversely,
Weissmann and Bea Navarro are attempting a similar
experiment by the transgenic route using promoters
specific to the peripheral nervous system.
Since manipulation of the immune system seemed easier
to accomplish, we sought to identify specific cell types in
lymphoid organs which might be relevant to neuroinvasion.
At this point, I was extremely lucky to elicit in Rolf
Zinkernagel some interest for this project. Zinkernagel
was (and probably still is) not a fervent supporter of the
protein-only hypothesis: he was intrigued by the possibility
that prion diseases may be intimately connected to dysfunc-
tions of the immune system although he never yielded to
pleas to explain such thoughts in more detail. Rolf
Zinkernagel and Hans Hengartner, who are conveniently
located one floor above us at the Institute of Experimental
Immunology in Zurich, had assembled a collection of
various immunodeficient mice gathered from laboratories
all over the world with specific defects of the immune
system, and made them available to us for inoculation
into brain and peripheral sites.
Michael Klein, who had joined my laboratory after a
postdoctoral period in experimental neuropathology in
Munich, took on the task of assessing the sensitivity to
scrapie of all these mutant strains. Contrary to
Zinkernagel’s guess (which he underlined by betting some
champagne with us on its correctness), all mice suffering
from immune deficiencies developed scrapie within the
normal latency when inoculated intracerebrally. After
intraperitoneal inoculation, however, all mice that lacked
terminally differentiated B-lymphocytes did not develop
disease (Table II), suggesting a crucial role for these cells
in the transport of prions (Klein et al., 1997). Even µMT
mice carrying a targeted disruption of the transmembrane
domain of the immunoglobulin µ chain, whose only defect
consists of lack of terminal maturation of B-cells (Kitamura
et al., 1991), were protected (Table II). Rico Frigg and
Michael Klein are now investigating whether the presence
of PrP on the surface of B-lymphocytes is important for
neuroinvasion: preliminary results indicate that we may
be in for some surprises with this particular experiment.
Homework for the next few years
Does any of the above bear any relevance to the BSE
crisis? Undoubtedly, it would be highly desirable to
develop some sort of post-exposure prophylaxis for prion
diseases, especially when one considers that a large
fraction of the population may have been exposed to the
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Fig. 3. Accumulation of PrPSc in brain grafts. Histoblots showing immunoreactive PrP in brain sections natively (first row) and after digestion with
increasing levels of proteinase K (second to fourth row). Prnpo/o mice (first column) show no immunoreactivity, while mock-inoculated tga20 mice
(which overexpress PrPC) show proteinase K-sensitive PrPC (second column), but no proteinase K-resistant PrPSc. Terminally sick scrapie-infected
wild-type mice contain large amounts of both PrPC and PrPSc (third column). Prnpo/o whose bone marrow has been reconstituted with wild-type
FLCs accumulate PrPSc in their PrPC-overexpressing grafts after i.c. (fourth column) but not after i.p. prion administration (fifth column).
Table II. Results of scrapie inoculation experiments into mice displaying various immune defects
Defect Genotype Strain Intracerebral inoculation Intraperitoneal inoculation
Scrapie Incubation Scrapie Incubation
(d 6 SD) (d 6 SD)
T cells CD 4–/– (Rahemtulla et al., 1991) C57BL/6 7/7 159 6 11 8/8 191 6 1
CD 8–/– (Fung Leung et al., 1991) C57BL/6 6/6 157 6 15 6/6 202 6 5
MHC-I–/– (Zijlstra et al., 1990) C57BL/6 8/8 162 6 11 7/7 211 6 6
perforin–/– (Ka¨gi et al., 1994) C57BL/6 3/4* 171 6 2 4/4 204 6 2
TCR–/– C57BL/6 6/6 148 6 7 9/9 191 6 13
B1T cells SCID (leaky) C57BL/6 7/8* 160 6 10 6/8 226 6 15
SCID C.B-17 4/4 152 6 1 0/8 healthy (.350)
RAG-2–/– (Shinkai et al., 1992) C57BL/6 7/7 167 6 2 0/7 healthy (.504)
RAG-1–/– (Mombaerts et al., 1992) C57BL/6 3/3 175 6 2 0/5 healthy (.270)
B1T cells 1 interferons AGR–/– (M.Suter, unpublished) 129 6/6 184 6 9 0/7 healthy (.470)
B cells, all immunoglobulins µMT (Kitamura et al., 1991) C57BL/6 8/8 181 6 6 0/8 healthy (. 612)
IgG, skewed IgM repertoire t11µMT (Klein et al., 1997) C57BL/6 5/5 170 6 2 4/4 223 6 2
FDC TNFR1–/– (Rothe et al., 1993) 129 7/7 165 6 3 9/9 216 6 10
wild-type 129 4/4 167 6 9 4/4 193 6 3
wild-type C57Bl/6 4/4 166 6 2 4/4 206 6 2
Mice with various immune defects were inoculated with RML scrapie prions intracerebrally or intraperitoneally. While all intracerebrally inoculated
mice developed scrapie with a latency similar to that of wild-type mice, intraperitoneal inoculation resulted in scrapie in T-cell deficient mice, but
not in mice displaying defects in the maturation of B-lymphocytes. SCID mice bred on the C57Bl/6 genetic background developed scrapie; however,
these mice are leaky (Bosma and Carroll, 1991; Nonoyama et al., 1993) and tend to contain a residual population of lymphocytes. FDC; follicular
dendritic cells.
BSE agent in Great Britain and continental Europe, but
this will only be possible if prionotropic molecules and
cells can be identified, which may offer a handle on
interfering with the spread of prions. It is unclear how
long prions persist in the body when their replication is
prevented (Aguzzi and Weissmann, 1998), but under
certain circumstances prion clearance may be rather fast.
Yet, total immune depletion does not represent a feasible
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practical solution for humans, except perhaps after massive
exposure at a known and well-defined time point (Aguzzi
and Collinge, 1997). Even selectively killing B-lympho-
cytes may be problematic. I deem it realistic to hope that
in the next few years the refinement of our understanding
of the mechanisms of prion neuroinvasion will lead to
the development of effective strategies of post-exposure
prophylaxis, and perhaps even of therapy.
Medal review
Finally, I do not want to leave unmentioned the unusual
events which have kept me busy in the first half of 1998.
Swiss scientists have recently escaped a terrible threat.
The population had been asked to vote on an amendment
of the Swiss Constitution that would ban all genetic
manipulation of animals, including worms and flies. Need-
less to say, this would have throttled Swiss biomedical
research. At the beginning of the year, the polls were
thoroughly negative and provoked a lot of gloom within the
Swiss research community. The neurografting experiments
described above seemed to be just the things that would
enrage the vociferous coalition of animal rights cam-
paigners and ‘gene protectionists’ who supported the
initiative. Consequently, my colleagues and I undertook
to go public and explain, in podium discussions, interviews
on radio, on TV and in the newspapers, what we were
doing and why. These activities demanded a large share
of our time and certainly affected scientific productivity
but, as a result, reason eventually prevailed and the ill-
conceived ‘gene protection’ initiative was defeated by a
2:1 ratio. The lesson I personally learned from these
events is that education of the population with respect to
the methods and the goals of science is just as much a
part of our job as experimental work. Take both tasks
seriously, and we will retain the support of the public.
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